CLINICAL_TRIALS
trial_result
· 2025-02-10
Clinical Trial Update: (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations [Phase 1]
Summary
Phase 1 study of BLU-451 for advanced cancers with EGFR Exon 20 insertion mutations has been terminated.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Blueprint Medicines Corporation | Conditions: Lung Neoplasm Malignant, Carcinoma, Non-Small-Cell Lung | Phase 1 | Status: TERMINATED